NCT06668077

Brief Summary

People with excess weight (EW) are characterized by high impulsivity, high levels of craving for high-calorie foods, deficits in inhibitory control, and maladaptive decision-making. These characteristics are related, at the brain level, to alterations in the activation of areas such as the dorsolateral prefrontal cortex (DLPFC) and its connectivity. The proposed intervention seeks to target these issues. Thus, the present study aims to characterize the effects of neuromodulation with intermittent theta burst transcranial magnetic stimulation (iTBS) of the DLPFC alone and in combination with inhibitory control training to produce brain, cognitive and behavioral changes, and modify altered biological parameters in people with EW. Participants will be randomly allocated to one of three groups: (1) a group that will receive active iTBS of the DLPFC combined with inhibitory control training with a food Go/No-go paradigm, (2) a group that will receive active iTBS of the DLPFC only, and (3) a control group that will receive sham iTBS. It is hypothesized that the combined intervention will obtain better results that the neuromodulation alone, and that both interventions, compared to sham iTBS, will achieve: (i) decreased body mass index, (ii) decreased craving, (iii) modified brain connectivity and activation both at rest and linked to task performance with food stimuli, (iv) improved anthropometric measures (waist circumference and waist-to-hip and waist-to-height ratios), (v) improved eating and exercise behaviors (decreased caloric intake and increased frequency and time of physical activity), (vi) improved emotional symptoms and emotional eating (depression, anxiety, emotional regulation, emotional eating, reward-related eating, non-homeostatic eating), (vii) improved cognitive abilities (motor and cognitive inhibition, delay of gratification, impulsivity, working memory, cognitive flexibility and decision making), (viii) changes in biological parameters associated to the interventions (plasma and microbiota), and (ix) advantages in cost-effectiveness and cost-utility based on economic evaluation analyses.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
141

participants targeted

Target at P50-P75 for not_applicable

Timeline
7mo left

Started Nov 2024

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress72%
Nov 2024Dec 2026

First Submitted

Initial submission to the registry

September 30, 2024

Completed
1 month until next milestone

First Posted

Study publicly available on registry

October 31, 2024

Completed
1 month until next milestone

Study Start

First participant enrolled

November 30, 2024

Completed
Same day until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 30, 2024

Completed
2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2026

Expected
Last Updated

February 14, 2025

Status Verified

February 1, 2025

Enrollment Period

Same day

First QC Date

September 30, 2024

Last Update Submit

February 11, 2025

Conditions

Keywords

excess weightoverweightinhibitory controlcognitive trainingiTBS

Outcome Measures

Primary Outcomes (2)

  • Body Mass Index (BMI)

    Change in BMI: Weight and height will be combined to report BMI in kg/m\^2. Weight will be obtained in kilograms with a digital scale (TANITA Corporation of America) and height in meters with a measuring rod (SECA Tape Measure 206).

    Pre-treatment assessment (week 2), post-treatment assessment (week 6) and follow-up (week 18)

  • Changes in brain activation during a inhibitory control task (neuroimaging measures)

    Food Go/No-go task (Based on the FoodTrainer App; Lawrence et al., 2015): Pictures appear and afterwards a green (Go signal) or red (No-Go signal) circle appears around them. Participants are instructed to score points by answering with a knob if the image is surrounded by a green circle, but not to press when the image is surrounded by a red circle. The presentation of the images is the same as in the FoodTrainer application: 50% of the images are food, with 100% of the healthy ones being presented under the 'Go' condition and 100% of the unhealthy ones under the 'No-Go' condition. The remaining 50% are non-food images, with 50-50% paired with 'Go' and 'No-Go' cues. In addition, participants can choose which categories of unhealthy foods they want to train. Brain activation to Go vs. No-Go stimuli and food vs. non-food stimuli will be compared. The task will be analysed to assess the brain activity associated with the task, using a psychophysiological interaction analysis(PPI).

    Pre-treatment assessment (week 2) and post-treatment assessment (week 6)

Secondary Outcomes (23)

  • Changes in Food decision-making (neuroimaging measures)

    Pre-treatment assessment (week 2) and post-treatment assessment (week 6)

  • Changes in Brain connectivity at rest (neuroimaging measures)

    Pre-treatment assessment (week 2) and post-treatment assessment (week 6)

  • Changes in White matter integrity (neuroimaging measures)

    Pre-treatment assessment (week 2) and post-treatment assessment (week 6)

  • Waist-to-height ratio (WHtR). Mean change from baseline at post-intervention

    Pre-treatment assessment (week 2), post-treatment assessment (week 6) and follow-up (week 18)

  • Food Craving. Mean change from baseline at post-intervention

    Pre-treatment assessment (week 2), post-treatment assessment (week 6) and follow-up (week 18)

  • +18 more secondary outcomes

Other Outcomes (25)

  • Descriptive measures

    Pre-treatment assessment (week 2)

  • Depression Symptoms. Screening

    Pre-treatment assessment (week 2)

  • Anxiety Symptoms. Screening

    Pre-treatment assessment (week 2)

  • +22 more other outcomes

Study Arms (3)

Combined intervention

EXPERIMENTAL

Experimental: Active iTBS of the DLPFC combined with inhibitory control training. An experimental group will receive: i) an informative session; ii) 4 pre treatment sessions (one assessment session with questionnaires, one with fMRI and one with biological samples. Also, a counselling session on diet and on physical exercise); iii) participate in 2 weekly individual intervention sessions that consist of iTBS of the left DLPFC (10 min) followed immediately by inhibitory control training for 10 minutes; iv) 3 sessions of post treatment assessment (one with questionnaires, one with fMRI and one with biological samples); v) 2 follow-up assessment sessions (3 months after completing the intervention) to repeat questionnaires and biological samples

Device: iTBS of the left DLPFCBehavioral: Inhibitory control training

Active iTBS

ACTIVE COMPARATOR

Experimental: Active iTBS of the DLPFC only. An experimental group will receive: i) an informative session; ii) 4 pre treatment sessions (one assessment session with questionnaires, one with fMRI and one with biological samples. Also, a counselling session on diet and on physical exercise); iii) participate in 2 weekly individual intervention sessions that consist of iTBS of the left DLPFC that will last about 10 minutes each; iv) 3 sessions of post treatment assessment (one with questionnaires, one with fMRI and one with biological samples); v) 2 follow-up assessment sessions (3 months after completing the intervention) to repeat questionnaires and biological samples

Device: iTBS of the left DLPFC

Sham iTBS

SHAM COMPARATOR

Control: iTBS of the vertex (sham). The control group will receive: i) an informative session; ii) 4 pre treatment sessions (one assessment session with questionnaires, one with fMRI and one with biological samples. Also, a counselling session on diet and on physical exercise); iii) participate in 2 weekly individual intervention sessions that consist of iTBS of the vertex that will last about 10 minutes each; iv) 3 sessions of post treatment assessment (one with questionnaires, one with fMRI and one with biological samples); v) 2 follow-up assessment sessions (3 months after completing the intervention) to repeat questionnaires and biological samples

Device: iTBS of the vertex

Interventions

Participants will receive a 3 minutes active theta burst transcranial magnetic stimulation (iTBS) of the DLPFC of the left hemisphere while not performing any other task

Also known as: Active iTBS
Active iTBSCombined intervention

Participants will receive a 3 minutes active theta burst transcranial magnetic stimulation (iTBS) of the vertex while not performing any other task

Also known as: Sham iTBS
Sham iTBS

Computerized cognitive training. Participants will perform the task of the FoodT app for 10 minutes during two weeks (taking advantage of time of maximum brain potentiation after the iTBS, Rossi et al., 2009). Images of food and non-food appear on the left, right or centre of the smart phone screen and participants must touch it (or not, depending on the cue) with their index finger as quickly as possible. Participants earn points for correct tap responses and lose points for incorrect tap responses. If the image has a green border around it, participants must tap the image and win 1 point. But if the image has a red border around it, participants must inhibit the tapping response, otherwise 1 point will be lost. Participants must respond as quickly and accurately as possible. Pictures of healthy and unhealthy foods are always paired with the Go and the No-Go signal, respectively. Non-food images are paired 50% of the time with the Go and the No-Go signal

Also known as: FoodT
Combined intervention

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • BMI between 25 and 39.9
  • Age between 18 and 60 years
  • Proficiency in the Spanish language
  • Right lateral dominance to avoid differential effects due to cortical hemispheric specialization

You may not qualify if:

  • Traumatic, digestive, metabolic or systemic disorders that affect the central nervous system, autonomic or endocrine
  • Severe psychopathological disorders and suicidal ideation or treatment for depression
  • Eating disorders
  • Contraindication for performing fMRI (pregnancy, metal implants, etc.) or iTBS (tinnitus, dizziness, surgical interventions, diseases or drugs that affect the CNS, etc.)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Mind, Brain and Behavior Research Center at University of Granada (CIMCYCUGR)

Granada, Spain

RECRUITING

Related Links

MeSH Terms

Conditions

OverweightObesityInhibition, Psychological

Condition Hierarchy (Ancestors)

OvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightSigns and SymptomsPathological Conditions, Signs and SymptomsBehavior

Study Officials

  • Raquel Vilar López, Ph.D.

    Universidad de Granada

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Raquel Vilar López, Ph.D.

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Masking Details
The psychologists that conduct the assessments (screening, assessment sessions and follow-ups) will be blinded to the group allocation during the whole project. Further, all participants will be blind to their condition. Also, the people who perform the statistical analyses will be blind to the condition of the groups, through the coding of the interventions. Only the therapist performing the interventions will not be blind to the allocation of the participants.
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Parallel group randomized controlled trial
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

September 30, 2024

First Posted

October 31, 2024

Study Start

November 30, 2024

Primary Completion

November 30, 2024

Study Completion (Estimated)

December 1, 2026

Last Updated

February 14, 2025

Record last verified: 2025-02

Data Sharing

IPD Sharing
Will share

All of the individual participant data collected during the trial, after deidentification, will be shared

Time Frame
Data will be available beginning 3 months and ending 5 years following article publication.
Access Criteria
Investigators whose proposed use of the data has been approved by an independent review committee and who provide a methodologically sound proposal. Proposals should be directed to rvilar@ugr.es

Locations